ERBB2 and cancer: Specifically, the results described above (figure 5D) brought us to the conclusion that solid-tumor targeted CAR T cells (eg, HER-2–CAR T cells) can ‘prepare’ (ie, sensitize by increasing PD-L1 expression) cancer cells and TME to the actions of PD-L1–CAR T cells.